Compare XBIO & SVRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XBIO | SVRE |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9M | 6.2M |
| IPO Year | 2011 | 2021 |
| Metric | XBIO | SVRE |
|---|---|---|
| Price | $4.33 | $2.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 33.7K | ★ 39.3K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.52 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,976,411.00 | N/A |
| Revenue This Year | $2.81 | $1,793.31 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.04 | N/A |
| 52 Week Low | $1.90 | $0.55 |
| 52 Week High | $13.93 | $6.30 |
| Indicator | XBIO | SVRE |
|---|---|---|
| Relative Strength Index (RSI) | 56.96 | 37.57 |
| Support Level | $2.61 | $2.02 |
| Resistance Level | $4.90 | $3.33 |
| Average True Range (ATR) | 0.29 | 0.30 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 31.72 | 14.04 |
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.
Saverone 2014 Ltd is engaged in the design, development, and commercialization of transportation and safety solutions, designed to prevent car accidents based on its patented technology of detecting, analyzing, and locating cellular phone radio frequency, or RF signals. The company is developing two product lines: the first is an In-Cabin Driver Distraction Prevention Solution (known as SaverOne system), or DDPS; and the second is an Advanced Driver-Assistance System, or ADAS, product that detects vulnerable road users, or VRUs, and provides a warning to the vehicle regarding potential collision. Geographically, Saverone generates maximum revenue from Europe and the rest from Israel.